• Explore /
  • Poster
  • / A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

Abstract Poster

Authors

John Powderly, II

John D. Powderly

Carolina BioOncology Institute, Huntersville, NC

John D. Powderly , Martin Gutierrez , Judy S. Wang , Erika P. Hamilton , Manish Sharma , Alexander I. Spira , Michael Millward , Mark J. Shackleton , Sophia Frentzas , Marianna Koczywas , Naveen Mehta , Ann Marie Christensen , Irina Shapiro , Kerry Whalen , Jennifer Michaelson , Patrick Baeuerle , John Edward Janik , Drew W. Rasco

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05117476

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2688)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2688

Abstract #

TPS2688

Poster Bd #

332a

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Sant P. Chawla

First Author: Drew W. Rasco

First Author: Yan Zhang